No profile data available.
Okyo Pharma Limited (OKYO) is a healthcare company in the eye treatment pharmaceuticals industry, based in London, United Kingdom, with about 5 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$4.71 million. Its market capitalization was $74.52 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Okyo Pharma reported $0 in revenue for fiscal year 2025.
$74.52 million as of October 9, 2026.
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Opus Genetics, Inc. (IRD), Outlook Therapeutics, Inc. (OTLK), Lenz Therapeutics, Inc. (LENZ), Aldeyra Therapeutics, Inc. (ALDX).